China-based CAR-T cell therapy specialist CARsgen Therapeutics Holdings Ltd. (HKG: 2171) has launched its BCMA-targeted CAR-T cell therapy, CT053 (zevorcabtagene autoleucel; zevor-cel), with a price tag of RMB 1.15 million (USD 160,000), as reported by The Paper, a local media outlet. The company anticipates that the drug’s annual end sales could exceed RMB 1 billion.
Recently granted approval for the treatment of recurrent or refractory multiple myeloma (MM) in patients who have seen disease progression after at least three lines of treatment, including at least one proteasome inhibitor and immunomodulatory agent, CARsgen’s therapy is bolstered by commercialization support from Huadong Medicine for the mainland China market.
In the Chinese market, aside from Juventas Cell Therapy Ltd’s CNCT19 (inaticabtagene autoleucel) priced at RMB 999,000, other CAR-T therapies are all priced over RMB 1 million. Fosun Kite’s Yescarta (axicabtagene ciloleucel) is priced at RMB 1.2 million, JW Therapeutics’s Carteyva (relmacabtagene autoleucel injection) at RMB 1.29 million, and Innovent/ IASO’s Fucaso (equecabtagene autoleucel) at RMB 1.16 million.- Flcube.com
